Key result
Routine pharmacological thromboprophylaxis is currently not indicated for ambulatory patients with gastrointestinal malignancy receiving neoadjuvant chemoradiotherapy due to a lack of robust data.
Why the study?
Does pharmacological thromboprophylaxis prevent thromboembolism in ambulatory patients receiving neoadjuvant chemoradiotherapy for gastrointestinal cancer?
Does pharmacological thromboprophylaxis prevent thromboembolism in ambulatory patients receiving neoadjuvant chemoradiotherapy for gastrointestinal cancer?
Answers are grounded in this paper and cite their sources.
There is an urgent need for robust data regarding thromboprophylaxis in ambulatory patients receiving neoadjuvant chemoradiotherapy for gastrointestinal cancer, as current guidelines recommend against it due to lack of evidence.
Thromboembolism a common, costly, and morbid complication that is also associated with decreased survival in cancer patients. The risk of thromboembolism in cancer patients is underappreciated. In addition to symptomatic deep venous thrombosis and pulmonary embolism, asymptomatic and arterial thromboembolic events are important consideration in ambulatory cancer patients receiving neoadjuvant chemoradiotherapy (nCRT). No specific randomized trial examining thromboprophylaxis (TP) during nCRT for gastrointestinal cancer has been performed, and none is accruing. Most guidelines currently recommend against TP in ambulatory cancer patients due to a lack of data rather than proof of harm or lack of efficacy. It is clear that robust data are urgently required, and that treatment with nCRT in patients with gastrointestinal malignancy is not an indication for routine pharmacological TP at the present time.
No takes yet. Share an insight, caveat, or question.
Smart et al. (2013) conducted a review in Gastrointestinal cancer. Thromboprophylaxis was evaluated. Routine pharmacological thromboprophylaxis is currently not indicated for ambulatory patients with gastrointestinal malignancy receiving neoadjuvant chemoradiotherapy due to a lack of robust data.
Synapse has enriched 10 related papers. Consider them for comparative context: